Skin CancerNCT07177638
A Community-based Educational Initiative to Raise Awareness of Melanoma and Other Skin Cancers.
A study testing Education Sessions to Improve Melanoma Knowledge and Awareness in people with Skin Cancer, run by NYU Langone Health at 1 site in United States.
Trial summary
This is a pilot study of a community- based melanoma educational intervention in Bensonhurst, Brooklyn conducted in-person by a community-health worker employed by the Perlmutter Cancer Center. Sample size will be around 35 participants. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Skin Cancer
- What is being tested?
- Education Sessions to Improve Melanoma Knowledge and Awareness
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45 participants
- Where
- 1 siteUnited States
- Study dates
- 13 Aug 2025to 30 Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Above 18 years of age
- Individuals who understand and speak either English or Russian
- Willingness and ability to consent and participate in the study
Who cannot join
- Under 18 years of age
- Individuals who do not understand and speak either English or Russian
- Individuals who participated in the focus group portion of a related study.
Trial locations and contacts
1 site in 1 country.
United States1 site
Jewish Community House of Bensonhurst
Brooklyn, New York, 11214
About this study
Official title: A Community-based Educational Initiative to Raise Awareness of Melanoma and Other Skin Cancers: Pilot Proof of Concept Study
This is a pilot study of a community- based melanoma educational intervention in Bensonhurst, Brooklyn conducted in-person by a community-health worker employed by the Perlmutter Cancer Center. Sample size will be around 35 participants. The participants will complete a pre-study survey and then take part in the educational session. There will be follow up study visits to assess the impact of the intervention on participant knowledge and skin self-examination behaviors at 3 weeks, 3 months, 6 months, and 12 months. At the 12-month mark, the participants will also complete a post-study survey.
- Conditions
- Skin Cancer
- Being tested
- Education Sessions to Improve Melanoma Knowledge and Awareness
- Keywords
- Melanoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Education, South Brooklyn
- Medical subject headings
- Skin Neoplasms, Melanoma, Carcinoma, Basal Cell, Carcinoma, Squamous Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Education Sessions to Improve Melanoma Knowledge and AwarenessBehavioural
Community based educational seminar led by a community health worker with follow-up questionnaires to assess knowledge retention and behavioral change.
| Study group | Role | What they receive |
|---|---|---|
| Adults from Bensonhurst County in Brooklyn, New York | Experimental | Participants will complete a pre-study survey and then take part in the educational session; follow-up visits to assess the impact of the intervention on participant knowledge and skin self-examination behaviors at will be held at 3 weeks, 3 months, 6 months, and 12 months. Participants will also complete a post-study survey at Month 12. Receives: Behavioral: Education Sessions to Improve Melanoma Knowledge and Awareness |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Melanoma Knowledge as Assessed by Questionnaire
Melanoma knowledge/awareness will be assessed using a study questionnaire. Each item is multiple choice with 1 correct answer: the total score is the percentage of correct responses and ranges from 0-100%.
Measured: Baseline, Immediately Post-Educational Session (Day 1)
Change in Melanoma Knowledge as Assessed by Questionnaire
Melanoma knowledge/awareness will be assessed using a study questionnaire. Each item is multiple choice with 1 correct answer: the total score is the percentage of correct responses and ranges from 0-100%.
Measured: Baseline, Week 3 Post-Intervention
Secondary outcomes (4)
Change in Melanoma Knowledge as Assessed by Questionnaire
Melanoma knowledge/awareness will be assessed using a study questionnaire. Each item is multiple choice with 1 correct answer: the total score is the percentage of correct responses and ranges from 0-100%.
Measured: Month 3 Post-Intervention, Month 6 Post-Intervention
Change in Melanoma Knowledge as Assessed by Questionnaire
Melanoma knowledge/awareness will be assessed using a study questionnaire. Each item is multiple choice with 1 correct answer: the total score is the percentage of correct responses and ranges from 0-100%.
Measured: Month 3 Post-Intervention, Month 12 Post-Intervention
Change in Number of Self-Skin Examinations
Assessed via survey.
Measured: Month 3 Post-Intervention, Month 6 Post-Intervention
Change in Number of Self-Skin Examinations
Assessed via survey.
Measured: Month 3 Post-Intervention, Month 12 Post-Intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Sep 2025
- Study start13 Aug 2025
- Primary completion30 Sep 2026 (estimated)
- Study completion30 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Skin CancerStudies of the same condition, open and under way.
- More trials run by NYU Langone HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 45 participants (actual)
Sponsor and investigators
- Lead sponsor
- NYU Langone Health
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- David Polsky, MD, PhD, Principal investigator, NYU Langone Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07177638
- Sponsor's protocol ID
- 24-00625
- Status last verified
- Jul 2026
- First submitted
- 10 Sep 2025
- Last updated
- 30 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: david.polsky@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Community-based Educational Initiative to Raise Awareness of Melanoma and Other Skin Cancers: Pilot Proof of Concept Study
- ClinicalTrials.gov ID
- NCT07177638
- Acronym / sponsor ID
- 24-00625
- Conditions
- Skin Cancer
- Keywords
- Melanoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Education, South Brooklyn
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 45 participants (actual)
- Lead sponsor
- NYU Langone HealthUniversity, hospital or other
- Study start
- 13 Aug 2025 (actual)
- Primary completion
- 30 Sep 2026 (estimated)
- Study completion
- 30 Sep 2026 (estimated)
- First posted
- 17 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a pilot study of a community- based melanoma educational intervention in Bensonhurst, Brooklyn conducted in-person by a community-health worker employed by the Perlmutter Cancer Center. Sample size will be around 35 participants. The participants will complete a pre-study survey and then take part in the educational session. There will be follow up study visits to assess the impact of the intervention on participant knowledge and skin self-examination behaviors at 3 weeks, 3 months, 6 months, and 12 months. At the 12-month mark, the participants will also complete a post-study survey.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Adults from Bensonhurst County in Brooklyn, New York | Experimental | Behavioral: Education Sessions to Improve Melanoma Knowledge and AwarenessParticipants will complete a pre-study survey and then take part in the educational session; follow-up visits to assess the impact of the intervention on participant knowledge and skin self-examination behaviors at will be held at 3 weeks, 3 months, 6 months, and 12 months. Participants will also complete a post-study survey at Month 12. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Above 18 years of age
- Individuals who understand and speak either English or Russian
- Willingness and ability to consent and participate in the study
Key exclusion criteria (3 listed)
- Under 18 years of age
- Individuals who do not understand and speak either English or Russian
- Individuals who participated in the focus group portion of a related study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Education Sessions to Improve Melanoma Knowledge and AwarenessCommunity based educational seminar led by a community health worker with follow-up questionnaires to assess knowledge retention and behavioral change. | Behavioural | Adults from Bensonhurst County in Brooklyn, New York |
Primary outcome
Change in Melanoma Knowledge as Assessed by Questionnaire
Time frame: Baseline, Immediately Post-Educational Session (Day 1)
Melanoma knowledge/awareness will be assessed using a study questionnaire. Each item is multiple choice with 1 correct answer: the total score is the percentage of correct responses and ranges from 0-100%.
Change in Melanoma Knowledge as Assessed by Questionnaire
Time frame: Baseline, Week 3 Post-Intervention
Melanoma knowledge/awareness will be assessed using a study questionnaire. Each item is multiple choice with 1 correct answer: the total score is the percentage of correct responses and ranges from 0-100%.
4 secondary outcomes
Change in Melanoma Knowledge as Assessed by Questionnaire
Time frame: Month 3 Post-Intervention, Month 6 Post-Intervention
Change in Melanoma Knowledge as Assessed by Questionnaire
Time frame: Month 3 Post-Intervention, Month 12 Post-Intervention
Change in Number of Self-Skin Examinations
Time frame: Month 3 Post-Intervention, Month 6 Post-Intervention
Change in Number of Self-Skin Examinations
Time frame: Month 3 Post-Intervention, Month 12 Post-Intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2026.
- Individual participant dataSharing planned: Yes. The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: david.polsky@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.
Related trials for Skin Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
Metastatic Melanoma
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Polsky, MD, PhD principal investigator
NYU Langone Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Education Sessions to Improve Melanoma Knowledge and Awareness in people with Skin Cancer, run by NYU Langone Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 30 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Melanoma Knowledge as Assessed by Questionnaire (time frame: Baseline, Immediately Post-Educational Session (Day 1)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2026.